| Autor: |
Žigić, Denis, Halilbašić, Amir, Husarić, Edin, Hotić, Nešad, Suljendić, Sanimir, Rahmanović, Emir |
| Předmět: |
|
| Zdroj: |
Central European Journal of Paediatrics; 2023, Vol. 19 Issue 1, p41-44, 4p |
| Abstrakt: |
Objective -- We report our initial experience with intralesional bleomycin sclerotherapy of macrocystic lymphangiomas in three pediatric patients. Case Reports -- Case 1. A 3.5-month-old male child presented to our institution with a radiologically verified macrocystic lymphangioma of the left thoracoabdominal region. After 2 cycles of sclerotherapy complete regression of the tumefact was achieved. Case 2. A 23-month-old male child presented with a radiologically confirmed lymphangioma in the sternal region. In total, he underwent 6 cycles of sclerotherapy in about 7 months. At first there was no response to therapy, but after the last cycle, the end result was excellent. Case 3. A 2-month-old male child presented with a radiologically confirmed lymphangioma of the left axillary region. He underwent 4 cycles of sclerotherapy in 4 months. The end result was excellent - complete regression of the tumefact. Conclusion -- In all our cases, intralesional bleomycin sclerotherapy was successful alone and showed very good end results. There were no serious side effects in any of our cases. Therefore, bleomycin is a safe alternative to surgical treatment of lymphangiomas in the pediatric population. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
